1.Supraclavicular Brachial Plexus Block with Arm-Hyperabduction .
Keoun KIM ; Hwa Taek KIM ; Dong Keoun KIM ; Wook PARK ; Sung Yell KIM ; Hung Kun OH
Korean Journal of Anesthesiology 1980;13(2):140-148
With the arm in hyperabduction, we have carried out 525 procedures of supraclavicularbrachial plexus block from Aug. 1976 to June 1980, whereas block with the arm in adduction has been customarily performed by other authors. The anesthetic procedure is as follows: 1) The patient lies in the dorsal recumbent position without a pillow under his head or shoulder. His arm is hyperabducted more than a 90 degree angle from his side, and his head is turned to the side opposite from that to be blocked. 2) An "X" is marked at a point 1 cm above the mid clavicle, immediately lateral to the edge of the anterior scalene muscle, and on the palpable portion of the subclavian artery. The area is aseptically prepared and draped. 3) A 22 gauge 3. 5cm needle attached to a syringe filled with 2% lidocaine (7~8mg/kg of body weight) and epineprine(1: 200,000) is inserted caudally toward the second portion of the artery where it crosses the first rib and parallel with the lateral border of the muscle until a paresthesia is obtained. 4) Paresthesia is usually elicited while inserting the needle tip about 1~2 cm in depth. If so, the local anesthetic solution is injected after careful aspiration. 5) If no paresthesia is elicited, the needle is withdrawn and redirected in an attempt to elicit paresthesia. 6) If, after several attempts, no paresthesia is obtained, the local anesthetic solution is injected into the perivascular sheath after confirming that the artery is not punctured. 7) Immediately after starting surgery, Valium is injected for sedation by the intravenous route in almost all cases. The age distribution of the cases was from 11 to 80 years. Sex distribution was 476 males and 49 females(Table 1). Operative procedures consisted of 103 open reductions, 114 skin grafts combined with spinal anesthesia in 14, 87 debridements, 75 repairs, i.e. tendon(41), nerve(32), and artery(2), 58 corrections of abnormalities, 27 amputations above the elbow(5), below the elbow(3) and fingers(17), 20 primary closures, 18 incisions and curettages, 2 replantations of cut fingers respectively(Table 2). Paresthesia was obtained in all cases. Onset of analgesia occurred within 5 minutes, starting in the deltoid region in almost all cases. Complete anesthesia of the entire arm appeared within 10 minutes but was delayed 15 to 20 minutes in 5 cases and failed in one case. Thus, our success rate was nearly 100%. The duration of anesthesia after a single injection ranged from 3(1/2), to 4(1/2) hours in 94% of the cases. The operative time ranged from 0.5 to 4 hours in 92.4% of the cases(Table 3). Repeat blocks were carried out in 33 cases when operative times which were more than 4 hours in 22 cases and the others were completed within 4 hours(Table 4). Two patients of the 33 cases, who received microvasular surgery were injected twice with 2% lidocaine 20ml, for a total of 13(1/2) hours. The 157 patients who received surgery on the forearms or hands had pneumatic tourniguets (250 torrs) applied without tourniquet pain. There was no pneumothorax, hematoma or phrenic nerve paralysis in any of the unilateraI and 27 bilateral blocks, but there was hoarseness in two, Horner's syndrome in 11 and shivering in 7 cases. No general seizures or other side effects were observed. By 20ml of 60% urografin study, we confirm ed the position of the needle tip to be in a safer position when the arm is in hyperabduction than when it is in adduction. And also that the humoral head caused some obstraction of the distal flow of the dye, indicating that less local anesthetic solution would be needed for satisfactory anesthesia. (Fig. 3,4)
Age Distribution
;
Amputation
;
Analgesia
;
Anesthesia
;
Anesthesia, Spinal
;
Arm
;
Arteries
;
Brachial Plexus Block*
;
Brachial Plexus*
;
Clavicle
;
Curettage
;
Debridement
;
Diatrizoate Meglumine
;
Diazepam
;
Fingers
;
Forearm
;
Hand
;
Head
;
Hematoma
;
Hoarseness
;
Horner Syndrome
;
Humans
;
Lidocaine
;
Male
;
Needles
;
Operative Time
;
Paralysis
;
Paresthesia
;
Phrenic Nerve
;
Pneumothorax
;
Replantation
;
Ribs
;
Seizures
;
Sex Distribution
;
Shivering
;
Shoulder
;
Skin
;
Subclavian Artery
;
Surgical Procedures, Operative
;
Syringes
;
Tourniquets
;
Transplants
2.Construction of Recombinant Adeno-Associated Virus Vector (AAVCMVp53) for Human Cervical Cancer Gene Therapy.
Yong Wook KIM ; Min Je SEO ; Su Mi BAE ; Jin Keoun JUN ; Tae Hyung KIM ; Tae Young JIN ; Suk Woo LEE ; Yong Wan KIM ; Chong Kook KIM ; Joon Mo LEE ; Sung Eun NAMKOONG ; Woong Shick AHN
Korean Journal of Obstetrics and Gynecology 2004;47(4):695-701
OBJECTIVE: To eliminate the potential problem of adenovirus contamination during recombinant adeno-associated virus (rAAV) vector production, we investigated new rAAV production method by a triple transfection of vector plasmid, packaging plasmid, and adenovirus helper plasmid. METHODS: This study was carried by triple transfection for the production of recombinant adeno-associated virus vector. This new production system was conducted with a plasmid construct which contained a mini-adenovirus genome capable of propagation of rAAV in the presence of adeno-assoceated viral rep and cap genes. To examine the helper functions of adenoviral plasmid on the production of rAAV vector, we carried out cotransfection with three plasmids, AAV vector, packaging construct, and adenovirus helper plasmids. The optimized plasmid quantity of transfection by calcium phosphate precipitation method was 25 micro gram of total plasmid DNA per 10 cm diameter plate of 293 cell. RESULTS: We found that rAAV yields peaked at 48 hr after Ad infection. The titer of rAAV was measured by the dot blot analysis to measure the number of particles/mL based on the quantification of viral DNA. CONCLUSION: We constructed recombinant AAVp53 without adenovirus contamination. We thought that we construct high titer rAAVp53 particle through HPLC column in the near future.
Adenoviridae
;
Calcium
;
Chromatography, High Pressure Liquid
;
Dependovirus*
;
DNA
;
DNA, Viral
;
Genetic Therapy*
;
Genome
;
Humans*
;
Plasmids
;
Product Packaging
;
Transfection
;
Uterine Cervical Neoplasms*